Izaskun Zeberio

Hematologist Hematology and Oncology Institute Donostia

[Izaskun Zeberio @ixazebe]

Infections after CAR-T @gloria_iacoboni #EHA2026

[Lymphoma Hub @lymphomahub]

CONGRESS | #EHA2026 | PRESENTATION

Matthew R. Wilson, Beatson West of Scotland Cancer Centre, Glasgow, presents findings from an international retrospective analysis evaluating HD-MTX for CNS relapse prophylaxis in patients with ultra high-risk LBCL receiving curative-intent chemoimmunotherapy (N = 1,923; HD-MTX, n = 872; no HD-MTX, n = 1,051).

HD-MTX did not significantly reduce 3-year CNS relapse vs no HD-MTX in UHR patients (6.6% vs 6.7%; adjusted HR, 0.95). Rates of isolated CNS relapse were also similar with HD-MTX vs no HD-MTX (4.8% vs 6.6%; adjusted HR, 0.81). In propensity score matching (501 pairs), 3-year CNS relapse was 7.4% vs 6.2% (HR, 0.86), and isolated CNS relapse was 5.3% vs 4.5% (HR, 0.83). No benefit was seen in any individual ultra high-risk subgroup. In the matched cohort, 3-year EFS and OS were similar with HD-MTX vs no HD-MTX (73.8% vs 73.7%; p = 0.65 and 82.6% vs 82.7%; p = 0.94).

Follow our live feed for more updates: https://t.co/SucPqSTkNI

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#lymphoma #lymsm #MedicalCongress @mattwilson2287

[Kate Cwynarski @CwynKate]

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/63890j5Upb

[Izaskun Zeberio @ixazebe]

Education&mentoring award #EHA2026 @DrRaulCordoba Congratulations Raul! Well deserved! Our ambassador!

[Fina Climent Esteller @fina_climent]

We are proud to share the program for the Club de Linfomas which will take place in Lleida on June 19. Don’t miss it. #hematopathology @SEAP_IAP @harnaulleida @IRBLleida_Info

[Izaskun Zeberio @ixazebe]

“Mujeres de Hierro” https://t.co/aKQ8I41oSa

[Mikel Izquierdo @mikelizquierdo_]

El ejercicio físico no puede quedarse en un consejo de pasillo. Tiene dosis, indicaciones y mecanismo de acción como cualquier fármaco, y en muchas enfermedades es el mejor tratamiento, no solo el complemento. Prescribirlo no es opcional: es medicina basada en la evidencia. @HoyPorHoy @La_SER @Nunodomin

[Ajay Major, MD, MBA @majorajay]

Hans IHC vs GEP for DLBCL COO classification #EHA2026
Large meta-analysis (19 studies, 2247 tumors) to eval noninferiority of Hans IHC to GEP.
Estimated accuracy:
- Hans IHC 90%
- pooled GEP 95%
- 4.5% difference met noninferiority margin
- sens 6.5% / NPV 6.4%
Supports Hans IHC as a practical & reliable procedure for COO classification in DLBCL. Particularly important with pola non-GC data. #lymsm cc @AshAlizadeh @gvencut1
https://t.co/NA59xg9kuY

[Izaskun Zeberio @ixazebe]

How I treat HLH-like toxicities after immune effector cell therapy https://t.co/8sfVwFQrXQ

[Ajay Major, MD, MBA @majorajay]

Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL:
- 120 pts actively receiving BsAb tx
- fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco)
- no difference in infusion time between IV and SQ
Time-limited & less frequent BsAb dosing translates into meaningful reductions in time toxicity, both in the clinic and at home. #lymsm
https://t.co/ci6lfcT5Ol

[Kai Rejeski @KRejeski]

💡How can we prevent infections in adult patients receiving bispecifics for lymphoma or myeloma?

Pleased to share our new How I Treat article, just published in @BloodPortfolio 👇

Great experience writing this with @RahulBanerjeeMD and @JoshuaHillMD !

https://t.co/C08M8ZvwE7

[SSBMT الخلاياالجذعية @SSBMT]

Shifting focus to clinical advancements!
​Dr. Izaskun Zeberio is currently on stage presenting on malignant hematology, diving deep into the most recent updates and breakthroughs in Hodgkin Lymphoma (HL). Vital insights for our specialized nursing community!
​#SSBMT #EBMT #SaudiHemOncNursing #SaudiHematology

[Mikel Izquierdo @mikelizquierdo_]

Gracias a @Technogym por la invitación al Innovation Outlook en Valencia.

En tiempos donde cada semana aparece un nuevo “crecepelo” de la longevidad —biohacking, suplementos milagro y promesas antiaging— conviene recordar algo simple: la longevidad que importa es la longevidad funcional.

No se trata solo de vivir más.
Se trata de llegar con fuerza, movilidad, autonomía y capacidad funcional.

Y ahí el ejercicio físico y el fitness no son lifestyle. Son infraestructura de salud.

#HealthyLongevity #ExerciseIsMedicine #Fitness #Aging #VIVIFRAIL @CIBER_ISCIII
@UNavarra
@navarrabiomed @semeg_es @ConsejoCOLEF

[Izaskun Zeberio @ixazebe]

Visión desde Hematología del impacto del ejercicio físico adaptado e individualizado en pacientes con linfoma. Gracias al Hospital Universitario de Canarias
por la invitación! #edonola #osakidetza #EHU #Biogipuzkoa

[Ajay Major, MD, MBA @majorajay]

NAVD real-world outcomes #lymsm
- 327 pts, med age 37, 24% ≥60 yrs
- ORR 94% (CR 86%)
- 1-yr PFS 94.5%, OS 99.7%
- irAEs in 29% (9% G3+)
- febrile neutropenia 10%, infections 25% (10% G3+)
RW efficacy mirrors S1826, though notably ⬆️ infections (despite GCSF) & irAEs.
https://t.co/YyWRSQxhKu

[CU Anschutz Lymphoma Program @CULymphoma]

Dr. @majorajay @CUHematology contributed to a multicenter study of nivo-AVD outcomes outside of the clinical trial setting, now published @Hemasphere_EHA. #lymsm https://t.co/Kbj2JqnxAb

[Izaskun Zeberio @ixazebe]

International Quality Innovation Conferences Award Ceremony in Donostia . Innovations in Health Care
Award Winner: Donostialdea Integrated Health Organization (IHO)- Basque Health Service (Osakidetza) Basque Countr #osakidetza #osidonostialdea #Biogipuzkoa Team effort!

[Izaskun Zeberio @ixazebe]

@AstridPavlovsky Fantástico programa y ponentes!

[Astrid Pavlovsky @AstridPavlovsky]

Los esperamos !

[Ajay Major, MD, MBA @majorajay]

Stage IA NLPHL outcomes @glow_nlphl
- 779/2243 pts Stage IA
- completely resected: better PFS if +RT
- unresected: R monotx & ABVD with worse PFS as compared to RT +/- ABVD
- not enough N to analyze R-CHOP
RT alone great option in both resected & unresected dx. #lymsm
https://t.co/i6SX235oo0